PRINCETON, N.J., March 30 /PRNewswire-FirstCall/ -- Pharmasset, Inc. announces management will present at the upcoming Citi Fourth Annual Biotech Day Conference and the Canaccord Adams Hepatitis C Conference. The Citi conference will be held in New York (April 1), while the Canaccord Adams conference will be held at the InterContinental The Barclay New York Hotel in New York City (April 7).
Schaefer Price, Pharmasset’s President and Chief Executive Officer, will provide an overview of the Company at the Citi conference on Wednesday, April 1, 2009 at 4:00 PM (ET) and review the Company’s HCV drug pipeline at the Canaccord Adams conference on Tuesday, April 7, 2009 at 1:30 PM (ET).
To access a simultaneous webcast of Mr. Price’s presentations via the internet, log on to the “Events & Presentations” section of the Investor Center on Pharmasset’s website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.
A replay of the webcast will be available on Pharmasset’s website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the “Events & Presentations” section of the Investor Center on Pharmasset’s website at http://investor.pharmasset.com/events.cfm .
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing four product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America, Europe, Japan and Taiwan. Clevudine is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. An IND for PSI-7851, a second generation nucleotide HCV inhibitor was filed in January 2009. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Forward-Looking Statements
Pharmasset “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are “forward-looking statements” that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended December 31, 2008 filed with the Securities and Exchange Commission entitled “Risk Factors” and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.
CONTACT: Richard E. T. Smith, Ph.D., VP, Investor Relations and Corporate
Communications, +1-609-613-4181, richard.smith@pharmasset.com
Web site: http://investor.pharmasset.com/events.cfm/
http://www.pharmasset.com/
